Treatment patterns, outcomes and health care resource utilization in advanced NSCLC patients without actionable mutations following introduction of immunotherapy: Japan Real-World Evidence in Lung Cancer - Immuno-Oncology

MSD K.K.0 个研究点目标入组 2,300 人开始时间: 2019年9月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•a. Patient started first-line systemic anti-cancer treatment for advanced NSCLC (stage IIIB-C/IV) at a participating center from July 1, 2017 through December 20, 2018 (retrospective identification in Cohort 1) or patient will start first-line systemic anti-cancer treatment for advanced NSCLC (stage IIIB-C/IV) at a participating center during the enrollment period (prospective identification in Cohort 2).
•b. Patient's advanced NSCLC diagnosis was histologically or cytologically confirmed prior to starting systemic anti-cancer treatment.
•c. Patient is at least 20 years of age at diagnosis of advanced NSCLC.
•d. Informed consent requirements or other requirements set forth by the local ethics committee have been met for patient.
•e. Patient has PD-L1 results available on or before the index date (Cohort 1 only)

•a.Patient received/will receive first-line systemic anti-cancer treatment as a clinical trial participant.
•b.Patient has tumors with actionable gene alterations with results documented on or before the index date (Cohort 1) or at the time of enrollment (Cohort 2).
•c.Investigator determines the patient is ineligible due to incomplete medical records on the index date (Cohort 1) or at the time of enrollment (Cohort 2).

发起方